Published on European Cystic Fibrosis Society (ECFS) (https://www.ecfs.eu)

Home > Understanding rates of and factors associated with elexacaftor/tezacaftor/ivacaftor (ETI) prescription

Understanding rates of and factors associated with elexacaftor/tezacaftor/ivacaftor (ETI) prescription

Resource Type

CF Research News

Authors

Georgene E Hergenroeder, Jonathan V Todd, Josh S Ostrenga, Christopher H Goss, Raksha Jain, Wayne Morgan, Gregory S Sawicki, Michael S Schechter, Elizabeth A Cromwell, Clement L Ren

References

J Cyst Fibros. 2024 Oct 28:S1569-1993(24)01801-0. doi: 10.1016/j.jcf.2024.10.006.

Document

PDF icon CF Research News Article [1]

Link

Scientific Abstract [2]

Keywords

CFTR modulator [3]
Elexacaftor/tezacaftor/ivacaftor [4]

Date

Monday, October 28, 2024

Featured resource article

Yes

Resource - Guideline Type

Other Guidelines [5]
Source URL:https://www.ecfs.eu/resource-article/cf-research-news/understanding-rates-and-factors-associated

Links
[1] https://www.ecfs.eu/sites/default/files/cf-research-article-files/JCF-D-24-00267R2_FINAL_Hergenroeder_151224.pdf [2] https://pubmed.ncbi.nlm.nih.gov/39472230/ [3] https://www.ecfs.eu/research-article-keywords/cftr-modulator [4] https://www.ecfs.eu/research-article-keywords/elexacaftortezacaftorivacaftor [5] https://www.ecfs.eu/resource-guideline-type/other-guidelines